[Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study].
This controlled study was performed on 36 patients affected by HBV and/or HCV correlated chronic hepatitis (CAH). Eighteen of them received 300 mg of UDCA-hemisuccinate orally twice a day for six months; the other 18 received 200 mg of S-adenosyl-methionine (SAMe) twice a day for six months. The two groups were determined randomly. Treatment with UDCA-hemi-succinate produced a statistically significant reduction in ALT (from 167 +/- 17 to 119 +/- 15 U/l; p < 0.0001), AST (from 122 +/- 14 to 86 +/- 11 U/l; p < 0.0001) and y-GT (from 81 +/- 10 to 53 +/- 6 U/l, p < 0.0001). The results obtained suggest that UDCA-hemi-succinate may be useful in the long-term treatment of chronic liver diseases of viral aetiology because it improves the biochemical parameters of hepatocellular necrosis and/or increased liver cell permeability.
Buzzelli
G
G
Istituto di Clinica Medica II, Università degli Studi di Firenze.
Moscarella
S
S
Focardi
G
G
Dattolo
P
P
Giusti
A
A
Calviani
L
L
Relli
P
P
Gentilini
P
P
D000328:Adult; D000368:Aged; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006521:Hepatitis, Chronic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012436:S-Adenosylmethionine / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D014580:Ursodeoxycholic Acid; D012436:S-Adenosylmethionine
L'emisuccinato dell'acido ursodesossicolico nel trattamento dell'epatite cronica attiva. Studio clinico-terapeutico controllato.